Competitive diffusion of new prescription drugs: The role of pharmaceutical marketing investment

Please use this identifier to cite or link to this item: http://hdl.handle.net/10045/44474
Full metadata record
Full metadata record
DC FieldValueLanguage
dc.contributorInvestigación en Marketinges
dc.contributor.authorRuiz-Conde, Enar-
dc.contributor.authorWieringa, Jaap E.-
dc.contributor.authorLeeflang, Peter S.H.-
dc.contributor.otherUniversidad de Alicante. Departamento de Marketinges
dc.date.accessioned2015-02-02T10:56:59Z-
dc.date.available2015-02-02T10:56:59Z-
dc.date.issued2014-10-
dc.identifier.citationTechnological Forecasting and Social Change. 2014, 88: 49-63. doi:10.1016/j.techfore.2014.06.006es
dc.identifier.issn0040-1625-
dc.identifier.urihttp://hdl.handle.net/10045/44474-
dc.description.abstractWe investigate the impact of marketing interventions on the diffusion of new products in a competitive setting. We develop a family of trial–repeat diffusion models to identify the longitudinal effects of marketing efforts, and complement this with a cross-sectional analysis to identify the between-drug effects. We believe that we are the first to consider both longitudinal and cross-sectional marketing effects in a trial–repeat diffusion context. The models are calibrated on 34 drugs in three therapeutic categories using monthly data. Our longitudinal analyses demonstrate that the trial rate responds positively to increases in own marketing expenditures but is affected negatively by competitors' expenditures. We show how these within-drug analyses provide opportunities for accelerating the diffusion process by reallocating marketing expenditures over time. The cross-sectional analyses demonstrate that pharmaceutical marketing has both an informative and a persuasive influence on the diffusion of new drugs. We find that direct-to-consumer advertising does not affect the trial nor repeat rates during the first months after introduction. We illustrate the managerial relevance of our results and find that a reallocation of marketing budgets does not alter the saturation level, but can help in attaining this level faster. We show that this has a great effect on sales, market share and ROI.es
dc.languageenges
dc.publisherElsevieres
dc.subjectTrial–repeat diffusion modelses
dc.subjectAdoption ratees
dc.subjectRepeat ratees
dc.subjectMarketing diffusiones
dc.subjectPharmaceutical marketinges
dc.subjectNew prescription drugses
dc.subject.otherComercialización e Investigación de Mercadoses
dc.titleCompetitive diffusion of new prescription drugs: The role of pharmaceutical marketing investmentes
dc.typeinfo:eu-repo/semantics/articlees
dc.peerreviewedsies
dc.identifier.doi10.1016/j.techfore.2014.06.006-
dc.relation.publisherversionhttp://dx.doi.org/10.1016/j.techfore.2014.06.006es
dc.rights.accessRightsinfo:eu-repo/semantics/restrictedAccesses
Appears in Collections:INV - Investigación en Marketing - Artículos de Revistas
INV - UA.BRANDSCIENCE - Artículos de Revistas

Files in This Item:
Files in This Item:
File Description SizeFormat 
Thumbnail2014_Ruiz_etal_TF&SC_final.pdfVersión final (acceso restringido)437,77 kBAdobe PDFOpen    Request a copy


Items in RUA are protected by copyright, with all rights reserved, unless otherwise indicated.